TY  - JOUR
AU  - Ríos-Tamayo, Rafael
AU  - Martín-García, Agustín
AU  - Alarcón-Payer, Carolina
AU  - Sánchez-Rodríguez, Dolores
AU  - de la Guardia, Ana María Del Valle Díaz
AU  - García Collado, Carlos Gustavo
AU  - Jiménez Morales, Alberto
AU  - Jurado Chacón, Manuel
AU  - Cabeza Barrera, José
PY  - 2017
DO  - 10.2147/DDDT.S115456
UR  - http://hdl.handle.net/10668/19499
T2  - Drug design, development and therapy
AB  - Multiple myeloma is a very heterogeneous disease with variable survival. Despite recent progress and the widespread use of new agents, patients with relapsed and refractory disease have a poor outcome. Immunomodulatory drugs play a key role in both...
LA  - en
KW  - dexamethasone
KW  - multiple myeloma
KW  - pomalidomide
KW  - triplet therapy
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Dexamethasone
KW  - Drug Design
KW  - Humans
KW  - Immunologic Factors
KW  - Multiple Myeloma
KW  - Survival Rate
KW  - Thalidomide
TI  - Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy.
TY  - research article
VL  - 11
ER  -